Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 2/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.49 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879560 | 1.00 | IL1RN (0.49) | IL1RNERAP2ERAP1GID4ACHE | |
| SCHEMBL12402720 | 1.00 | IL1RN (0.49) | IL1RNERAP2ERAP1GID4ACHE | |
| Hydrochloric Acid SCHEMBL2167605 | 0.98 | IL1RN (0.47) | IL1RNERAP2ERAP1GID4ACHE | |
| Hydrochloric Acid SCHEMBL29984305 | 0.98 | IL1RN (0.47) | IL1RNERAP2ERAP1GID4ACHE | |
| Hydrochloric Acid SCHEMBL2167296 | 0.98 | IL1RN (0.47) | IL1RNERAP2ERAP1GID4ACHE | |
| Hydrochloric Acid SCHEMBL23355920 | 0.98 | IL1RN (0.47) | IL1RNERAP2ERAP1GID4ACHE | |
| SCHEMBL17193124 | 0.89 | GID4 (0.42) | IL1RNERAP2ERAP1GID4ACHE | |
| SCHEMBL29983834 | 0.89 | GID4 (0.42) | IL1RNERAP2ERAP1GID4ACHE | |
| SCHEMBL4019181 | 0.89 | GID4 (0.42) | IL1RNERAP2ERAP1GID4ACHE | |
| SCHEMBL4206687 | 0.89 | GID4 (0.42) | IL1RNERAP2ERAP1GID4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | claimed |
| EP-2780324-B1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-05-17 | — | — | EP | claimed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | claimed |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | claimed |
| US-20240398772-A1 | OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) | 2024-12-05 | — | — | US | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230357219-A1 | PREPARATION OF BIARYL RING-LINKED AROMATIC HETEROCYCLIC DERIVATIVE AS IMMUNOMODULATOR AND USE THEREOF | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20210108245-A1 | Enantioselective Biocatalytic Preparation of 4-Cyano-Substituted 1-Aminoindane and Ozanimod | PHARMAZELL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20210108245-A1 | Enantioselective Biocatalytic Preparation of 4-Cyano-Substituted 1-Aminoindane and Ozanimod | PHARMAZELL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| CN-112513048-A | Sulfonylimide compounds as inhibitors of interleukin-1 activity | 豪夫迈·罗氏有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3775253-A1 | ENANTIOSELECTIVE BIOCATALYTIC PREPARATION OF 4-CYANO-SUBSTITUTED 1-AMINOINDANE AND OZANIMOD | Pharmazell GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-111971398-A | Enantioselective biocatalytic preparation of 4-cyano-substituted 1-aminoindan and azanidod | 泽尔制药有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1843820-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006083454-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | ALANTOS PHARMACEUTICALS, INC., | 2006-08-03 | — | — | US | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | IL1RN 3889/4885ERAP2 939/4885ERAP1 1556/4885 |
| US-20230357219-A1 | PREPARATION OF BIARYL RING-LINKED AROMATIC HETEROCYCLIC DERIVATIVE AS IMMUNOMODULATOR AND USE THEREOF | PDCD1, CD274, PDCD1LG2 | IL1RN 60/4885ERAP2 4766/4885ERAP1 4563/4885 |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | MMP13, MMP3, MMP11 | IL1RN 420/4885ERAP2 181/4885ERAP1 196/4885 |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | IL1RN 2112/4885ERAP2 3316/4885ERAP1 2640/4885 |
| US-20240398772-A1 | OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | OGFR, OPRL1, OPRM1 | IL1RN 368/4885ERAP2 1422/4885ERAP1 1625/4885 |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE7A, PDE5A, PDE2A | IL1RN 2794/4885ERAP2 881/4885ERAP1 492/4885 |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | IL1RN 2165/4885ERAP2 3308/4885ERAP1 2632/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | IL1RN 412/4885ERAP2 3068/4885ERAP1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.